Square Pharmaceuticals
Square Pharmaceuticals Limited, headquartered in Dhaka, Bangladesh, stands as a leading entity in the pharmaceutical industry. Founded in 1985, the company has established a robust presence across South Asia, focusing on the development, manufacturing, and marketing of a diverse range of pharmaceutical products. With a commitment to quality and innovation, Square Pharmaceuticals offers a wide array of medications, including prescription drugs, over-the-counter products, and herbal medicines. Their unique formulations and adherence to international standards have positioned them as a trusted name in healthcare. Recognised for their significant contributions to the industry, Square Pharmaceuticals has achieved numerous accolades, solidifying its market position as one of the top pharmaceutical companies in Bangladesh. Their dedication to research and development continues to drive advancements in healthcare solutions.
DitchCarbon Score
How does Square Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Square Pharmaceuticals's score of 16 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Square Pharmaceuticals's reported carbon emissions
In 2024, Square Pharmaceuticals, headquartered in Bangladesh (BD), reported total carbon emissions of approximately 60,000,000 kg CO2e from Scope 1 and about 4,387,000 kg CO2e from Scope 2. This data reflects the company's operational emissions, with Scope 1 emissions primarily arising from direct activities and Scope 2 emissions resulting from purchased electricity. Square Pharmaceuticals is a current subsidiary of Square Pharmaceuticals PLC, which influences its emissions reporting and climate commitments. However, the company has not disclosed any specific reduction targets or initiatives as part of its climate strategy. There are no available data on Scope 3 emissions, which typically encompass indirect emissions in the value chain. While Square Pharmaceuticals has not set formal science-based targets or climate pledges, the company is positioned within an industry increasingly focused on sustainability and carbon reduction. As such, it may benefit from aligning its practices with broader industry standards and expectations for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 59,705,000 |
| Scope 2 | 4,387,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Square Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
